Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials

Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association

(2018) Emelia J. Benjamin et al.   CIRCULATION

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

(2017) Clyde W. Yancy et al.   JOURNAL OF CARDIAC FAILURE

A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease

(2016) Naoki Sato et al.   CIRCULATION JOURNAL

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease

(2016) Gerasimos Filippatos et al.   EUROPEAN HEART JOURNAL

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2016) Piotr Ponikowski et al.   EUROPEAN JOURNAL OF HEART FAILURE

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy

(2015) George L. Bakris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy

(2015) Luis M. Ruilope et al.   AMERICAN JOURNAL OF NEPHROLOGY

Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury

(2014) Peter Kolkhof et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2013) Alessandro Liberati   ANNALS OF INTERNAL MEDICINE

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

(2013) Bertram Pitt et al.   EUROPEAN HEART JOURNAL

Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function

(2013) Romain Eschalier et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases

(2012) Lars Bärfacker et al.   ChemMedChem

Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart Failure

(2012) Orly Vardeny et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics

(2011) Peter Kolkhof et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

(2010) Georgia Salanti et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Aldosterone 'escape' vs 'breakthrough'

(2010) Robert W. Schrier   Nature Reviews Nephrology

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

(2010) Faiez Zannad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results

(2009) Alessandro Boccanelli et al.   EUROPEAN JOURNAL OF HEART FAILURE

Use of Aldosterone Antagonists in Heart Failure

(2009) Nancy M. Albert   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION